Get the Stockscreener App
1.8512
6.03%
-0.1188
MAIA Biotechnology Inc stock is traded at $1.8512, with a volume of 133.10K.
It is down -6.03% in the last 24 hours and down -0.47% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.97
Open:
$1.95
24h Volume:
133.10K
Relative Volume:
0.44
Market Cap:
$51.53M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.3414
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+0.06%
1M Performance:
-0.47%
6M Performance:
-31.44%
1Y Performance:
+34.14%
1-Day Range:
$1.74
$1.95
1-Week Range:
$1.71
$2.0898
52-Week Range:
$1.24
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.88 | 51.53M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.88 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.00 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.50 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.35 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
269.22 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology, Inc. to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - Marketscreener.com
Maia Biotechnology Plans to Begin Phase 3 Lung Cancer Trial of THIO-104 in H2 -February 27, 2025 at 10:58 am EST - Marketscreener.com
MAIA Biotechnology to initiate THIO-104 trial - TipRanks
Can MAIA's THIO Outperform Chemotherapy in Advanced Lung Cancer? Phase 3 Trial Will Decide - StockTitan
MAIA Biotechnology Secures $1.43 Million in Non-Brokered Private Placement - Defense World
MAIA Biotech announces trial design to expand THIO-101 Phase 2 NSCLC study - TipRanks
MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - StockTitan
MAIA Biotechnology expands phase 2 cancer trial - Investing.com
Can This Lung Cancer Treatment's 16.9-Month Survival Rate Transform Third-Line Therapy? - StockTitan
Maia Biotechnology director Stan Smith acquires $75,000 in stock - Investing.com India
Maia Biotechnology director Stan Smith acquires $75,000 in stock By Investing.com - Investing.com South Africa
MAIA Biotechnology announces non-brokered private placement of $1.43M - MSN
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million - BioSpace
Can This $4.1M Funding Push MAIA's Cancer Drug Trial to the Next Level? - StockTitan
MAIA Biotechnology announces $2.7M private placement - MSN
MAIA Biotechnology, Inc. announced that it expects to receive $2.715 million in funding -February 17, 2025 - Marketscreener.com
MAIA Biotechnology Announces Private Placement of $2,715,000 - BioSpace
MAIA Biotechnology secures $2.7 million in private placement - Investing.com India
MAIA Biotechnology secures $2.7 million in private placement By Investing.com - Investing.com South Africa
MAIA Biotechnology to sell 1.81M shares at $1.50 in private placement - TipRanks
MAIA Biotech Raises Strategic $2.7M with Insider Backing for Crucial Phase II Cancer Trial - StockTitan
MAIA Biotechnology announces updated data from THIO-101 trial - MSN
MAIA Biotech executives receive salary hikes and new terms - MSN
MAIA Biotech executives receive salary hikes and new terms By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Efficacy Updates for THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - Defense World
MAIA Biotechnology Amends Employment Agreements with Executive Officers - Defense World
MAIA Biotechnology Updates Executive Compensation Packages - TipRanks
MAIA Biotechnology Inc (MAIA) can make a big difference with a little luck - SETE News
Investing in MAIA Biotechnology Inc (MAIA) Is Getting More Attractive - Knox Daily
MAIA Biotechnology Reports Promising Phase 2 Trial Results - TipRanks
MAIA Biotechnology reports promising THIO trial results for NSCLC By Investing.com - Investing.com South Africa
MAIA Stock on the Rise: A Promising Investment - The InvestChronicle
Breaking down MAIA’s current quarter earnings estimates - US Post News
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology reports promising THIO trial results for NSCLC - Investing.com India
MAIA Biotechnology, Inc. Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - Marketscreener.com
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 0.5% Higher – What’s Next? - Defense World
Atara to cut 50% of workforce amid FDA woes (ATRA:NASDAQ) - Seeking Alpha
MAIA Biotechnology, BeiGene announce clinical supply agreement - The Cancer Letter
When Will MAIA Biotechnology Inc (AMEX: MAIA) Be A Good Investment? - Marketing Sentinel
Geode Capital Management LLC Grows Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotech to Present THIO Cancer Treatment Pipeline at Biotech Showcase 2025 - StockTitan
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene - MarketWatch
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications - BioSpace
MAIA Biotech partners with BeiGene for cancer trials - Investing.com
MAIA Biotechnology Directors Show Strong Confidence with $573K Personal Investment in Private Placement - StockTitan
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
MAIA Biotechnology Inc Stock (MAIA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Stan | Director |
Feb 24 '25 |
Buy |
1.50 |
50,000 |
75,000 |
1,180,060 |
| Smith Stan | Director |
Dec 13 '24 |
Buy |
1.87 |
25,000 |
46,800 |
1,130,060 |
| Guerrero Ramiro | Director |
Dec 13 '24 |
Buy |
1.87 |
53,418 |
99,998 |
514,970 |
| Luput Cristian | Director |
Nov 01 '24 |
Buy |
2.51 |
22,133 |
55,554 |
389,483 |
| CHAOUKI STEVEN M | Director |
Nov 01 '24 |
Buy |
2.51 |
22,133 |
55,554 |
111,024 |
| Guerrero Ramiro | Director |
Nov 01 '24 |
Buy |
2.51 |
88,534 |
222,220 |
408,134 |
| Smith Stan | Director |
Nov 01 '24 |
Buy |
2.51 |
100,000 |
251,000 |
957,568 |
| Louie Ngar Yee | Director |
Apr 25 '24 |
Buy |
2.03 |
19,665 |
39,920 |
1,167,189 |
| Smith Stan | Director |
Apr 25 '24 |
Buy |
2.03 |
147,492 |
299,409 |
1,005,060 |
| CHAOUKI STEVEN M | Director |
Mar 14 '24 |
Buy |
1.17 |
34,641 |
40,530 |
88,891 |
2.02%
0.62%
Cap:
|
Volume (24h):